Will Relay Therapeutics (RLAY) Board Additions Signal a Shift in Commercialization Strategy? [Yahoo! Finance]
Relay Therapeutics (NASDAQ:RLAY) had its price target raised by analysts at Wells Fargo & Company from $4.00 to $6.00. They now have an "equal weight" rating on the stock.
Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates [Yahoo! Finance]
Relay Therapeutics GAAP EPS of -$0.43 misses by $0.02 [Seeking Alpha]
Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates